FDA has lifted restrictions on studies of bluebird bio's bb1111 for the treatment of sickle cell disease. The FDA also lifted restrictions on studies of beti-cel for the treatment of transfusion-dependent Ξ²-thalassemia.
FDA has lifted restrictions on studies of bluebird bio's bb1111 for the treatment of sickle cell disease. The FDA also lifted restrictions on studies of beti-cel for the treatment of transfusion-dependent Ξ²-thalassemia. 
investor.bluebirdbio.com
English (US) 